London
· Delayed Price · Currency is GBP · Price in USD Vertex Pharmaceuticals Statistics
Total Valuation
LON:0QZU has a market cap or net worth of GBP 85.41 billion. The enterprise value is 78.06 billion.
| Market Cap | 85.41B |
| Enterprise Value | 78.06B |
Important Dates
The last earnings date was Monday, May 5, 2025.
| Earnings Date | May 5, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 256.80M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -1.20% |
| Shares Change (QoQ) | -0.38% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 256.16M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 23.22 |
| PS Ratio | 9.94 |
| PB Ratio | 6.69 |
| P/TBV Ratio | 7.37 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 21.74, with an EV/FCF ratio of -80.66.
| EV / Earnings | -101.99 |
| EV / Sales | 9.29 |
| EV / EBITDA | 21.74 |
| EV / EBIT | 23.40 |
| EV / FCF | -80.66 |
Financial Position
The company has a current ratio of 2.65, with a Debt / Equity ratio of 0.10.
| Current Ratio | 2.65 |
| Quick Ratio | 2.12 |
| Debt / Equity | 0.10 |
| Debt / EBITDA | 0.35 |
| Debt / FCF | -1.32 |
| Interest Coverage | 189.98 |
Financial Efficiency
Return on equity (ROE) is -5.64% and return on invested capital (ROIC) is 14.73%.
| Return on Equity (ROE) | -5.64% |
| Return on Assets (ROA) | 11.77% |
| Return on Invested Capital (ROIC) | 14.73% |
| Return on Capital Employed (ROCE) | 23.08% |
| Revenue Per Employee | 1.41M |
| Profits Per Employee | -125,475 |
| Employee Count | 6,100 |
| Asset Turnover | 0.47 |
| Inventory Turnover | 4.79 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +0.85% in the last 52 weeks. The beta is 0.51, so LON:0QZU's price volatility has been lower than the market average.
| Beta (5Y) | 0.51 |
| 52-Week Price Change | +0.85% |
| 50-Day Moving Average | 489.39 |
| 200-Day Moving Average | 470.58 |
| Relative Strength Index (RSI) | 27.31 |
| Average Volume (20 Days) | 1,092 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 2.25 |
Income Statement
In the last 12 months, LON:0QZU had revenue of GBP 8.59 billion and -765.40 million in losses. Loss per share was -2.97.
| Revenue | 8.59B |
| Gross Profit | 4.56B |
| Operating Income | 3.41B |
| Pretax Income | -232.35M |
| Net Income | -765.40M |
| EBITDA | 3.55B |
| EBIT | 3.41B |
| Loss Per Share | -2.97 |
Balance Sheet
The company has 4.80 billion in cash and 1.28 billion in debt, giving a net cash position of 7.51 billion.
| Cash & Cash Equivalents | 4.80B |
| Total Debt | 1.28B |
| Net Cash | 7.51B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 12.77B |
| Book Value Per Share | 49.69 |
| Working Capital | 4.82B |
Cash Flow
In the last 12 months, operating cash flow was -758.74 million and capital expenditures -208.98 million, giving a free cash flow of -967.72 million.
| Operating Cash Flow | -758.74M |
| Capital Expenditures | -208.98M |
| Free Cash Flow | -967.72M |
| FCF Per Share | n/a |
Margins
Gross margin is 53.09%, with operating and profit margins of 39.71% and -8.91%.
| Gross Margin | 53.09% |
| Operating Margin | 39.71% |
| Pretax Margin | -2.70% |
| Profit Margin | -8.91% |
| EBITDA Margin | 41.30% |
| EBIT Margin | 39.71% |
| FCF Margin | n/a |
Dividends & Yields
LON:0QZU does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 1.20% |
| Shareholder Yield | 1.20% |
| Earnings Yield | -0.90% |
| FCF Yield | -1.13% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
LON:0QZU has an Altman Z-Score of 13.24.
| Altman Z-Score | 13.24 |
| Piotroski F-Score | n/a |